ENEDYM
25.8.2021 11:32:09 CEST | Business Wire | Press release
Enedym Inc. ( “Enedym”), the technology company that develops next generation switched reluctance motors (SRMs), electric propulsion, and electrified powertrains, announced today that it formed a partnership with the Napino Group. (“Napino”), one of India's leading suppliers of automotive electronic products. Under the terms of the partnership, Napino will license Enedym’s switched reluctance motor (SRM) technology for use in 2-wheel electric motorcycles and scooters in India.
Dr. Ali Emadi, Founder, President, and CEO of Enedym commented, “We are excited to announce this deal with Napino. The partnership between Enedym and Napino is transformative and significant given it will provide a more stable and secure global manufacturing supply chain, combined with sustainable next generation motor technology. The landscape of the automotive industry is changing rapidly and we are excited to provide next generation electric motor technology that aligns with the needs of leading OEMs. Through the use of Enedym’s SRMs – which eliminate the need for rare earth metals often sourced exclusively from China – we are providing a gateway to low cost/high quality manufacturing of next generation motors, inverters, and controllers.
Dr. Emadi added, “We are in the midst of a historic shift, both in terms of electrification, focus on sustainability, and the need for secure and stable supply chains. Partnering with Napino will allow us to supply our next generation motor technology within a massive market and offer Indian based and global OEM’s a viable manufacturing alternative to China.”
Mr. Vaibhav Raheja, Joint Managing Director of Napino commented, “We are extremely delighted to announce our partnership with Enedym. Achieving removal of magnets and rare earth elements in these products offers great advantages not only from a geo-political point of view, but also ensures sensible use of natural resources. We are confident that the affordable and robust solution being created by our engineering & manufacturing teams will offer quicker adoption of electric mobility in India. Our vision is to make India a global manufacturing hub for EV motors and contribute towards making it carbon neutral.”
Commenting on the partnership, Mr. Naveen Kumar, Group CEO of Napino, said; “Zero emission mobility has become a global movement & with Enedym as our partner, we are gearing up to meet the current & future requirements of electric mobility. As a technology driven organization, Napino has constantly reinforced its position as a leading Auto Electronics System Supplier, offering innovative, sustainable and robust solutions for its customers. Working on cutting-edge technologies ensures that we continue to be at the forefront of the rapidly transforming business landscape.”
Sumit Dhanuka, Founder & Managing Partner of Precog Innovation Partners, commented, "We are excited to have enabled this unique strategic partnership between Napino and Enedym. This collaboration brings together Enedym’s cutting-edge design and development capabilities in the SRM motor technology space and Napino’s strong automotive manufacturing and go-to-market strengths in the Indian market, helping us realize the shared vision towards Net-Zero Mobility and an Aatmanirbhar Bharat (Self-reliant India).”
Enedym recently announced a $15 million financing round from an international group of strategic investors within the U.S., Canada, Europe, and India.
About Enedym, Inc.
Enedym is a technology start-up company from McMaster University. The company is headquartered at the McMaster Innovation Park in Hamilton, Ontario, Canada. Enedym has ownership of over 50 patents and pending patent applications and related inventions developed by the Canada Excellence Research Chair in Hybrid Powertrain Dr. Ali Emadi and his research group at the McMaster Automotive Resource Centre (MARC), McMaster University. Enedym’s vision is to reduce the cost of electric propulsion motors significantly and power a new paradigm in the electric motor industry through novel switched reluctance motor (SRM) drive technologies. Enedym aspires to help save the planet, one electric motor market at a time. To learn more about Enedym, please visit www.enedym.com and our YouTube channel at Enedym YouTube .
Napino Auto & Electronics Ltd
Napino is one of India's leading supplier of automotive electronic products. It employs roughly 6000 employees. The portfolio includes ECUs, capacitor-discharge ignitor, regulator rectifier, wiring harness, handlebar switches, and E Mobility products among other electronic offerings. As a leader in its segment with complete design, development, and manufacturing capabilities, Napino offers innovative solutions to major automobile manufacturers. Through its robust R&D capabilities and sustainable partnerships with global players, Napino aspires to lead technology innovation in automotive electronics. To learn more, please visit http://napino.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005029/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom